

Personal Information**Shi Yuan-kai****Address:** National Cancer Center, China**Country:** China**Curriculum Vitae**

Prof. Shi graduated from China Medical University in 1984, started his practice and research in medical oncology in Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC) in 1988. From 1989 to 1992, he studied in Osaka University Medical School as a foreign student. From 1996 to 1997 he worked as a Visiting scholar in the Bone Marrow Transplantation Program, the University of Alabama at Birmingham (UAB), and From 2000 to 2001 in the University Texas MD Anderson Cancer Center.

Prof. Shi is a member of Advisory Committee for New Drug Evaluation, China Food & Drug Administration (CFDA) and Key Reviewer of China National Major Project for New Drug Innovation; Board Member of Asian Clinical Oncology Society (ACOS); President of Chinese Association of Clinical Oncologists (CACO); He is also the co-editor in chief of Asian Pacific Journal of Clinical Oncology and advisory board member of Nature Review Clinical Oncology.

Prof. Shi specializes in lung cancer, lymphoma, gastrointestinal cancer, breast cancer, urinary cancer and other solid tumor medical management. As the primary investigator he participated in over 160 clinical trials of anticancer drugs in the last 20 years. Make great contribution to many Chinese innovative new drug clinical studies, such as Icotinib and Chidamide. He has published over 350 papers in international and Chinese medical journals.

As the result of his outstanding work in research, clinical practice and medical education, Prof. Shi is the recipient of several awards, such as the 1st class prize of the State Science and Technology Advancement Award (Second Order) , the 1st class prize of Chinese Medical Science and Technology Award (First Order) , the 1st class prize of Chinese Pharmaceutical Science and Technology Award (First Order) , ACOS Yukio Kobayashi Award, etc.